首页> 美国卫生研究院文献>Molecular Medicine Reports >Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo
【2h】

Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo

机译:靶向STAT3的小分子干扰RNA和AZD0530在体外和体内对胶质母细胞瘤的协同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to explore the synergistic effect of signal transducer and activator of transcription 3 (STAT3)-targeted small interfering (si)RNA and AZD0530 against glioblastoma in vitro and in vivo. Glioblastoma cell lines U87 and U251 were divided into four groups and treated with control, LV-STAT3 siRNA, AZD0530, and combined LV-STAT3 siRNA with AZD0530, respectively. The proliferation and apoptotic capacity of glioblastoma cells was assessed by Cell Counting Kit-8 and double staining flow cytometry assays, respectively. Additionally, the potential effect of LV-STAT3 siRNA and AZD0530 on glioblastoma was evaluated in vivo. Images were captured of the tumor formation in mice every week. Following three weeks of treatment, NMR scan and immunohistochemistry were performed. The treatment of combined LV-STAT3 siRNA and AZD0530 was more effective in inhibiting proliferation and inducing apoptosisof glioblastoma cells in comparison with the treatment of either LV-STAT3 siRNA or AZD0530 alone. Although LV-STAT3 siRNA or AZD0530 treatment alone suppressed tumor growth in mice, the combined treatment had a more significant effect than the treatment of LV-STAT3 siRNA or AZD0530 alone. According to the results of both in vitro and in vivo assays, a combined therapy of LV-STAT3 siRNA with AZD0530 could enhance therapeutic effects on glioblastoma, supporting the idea that the combination of LV-STAT3 siRNA and AZD0530 could serve as a novel and effective strategy to combat glioblastoma.
机译:这项研究的目的是在体外和体内探索信号转导和转录激活因子(STAT3)靶向的小干扰(si)RNA和AZD0530对胶质母细胞瘤的协同作用。胶质母细胞瘤细胞系U87和U251分为四组,分别用对照LV-STAT3 siRNA,AZD0530和LV-STAT3 siRNA与AZD0530合并处理。胶质母细胞瘤细胞的增殖和凋亡能力分别通过Cell Counting Kit-8和双染色流式细胞术进行评估。另外,在体内评估了LV-STAT3 siRNA和AZD0530对胶质母细胞瘤的潜在作用。每周捕获小鼠中肿瘤形成的图像。治疗三周后,进行了NMR扫描和免疫组化。与单独使用LV-STAT3 siRNA或AZD0530的治疗相比,组合使用LV-STAT3 siRNA和AZD0530的治疗在抑制胶质母细胞瘤细胞增殖和诱导凋亡方面更有效。尽管单独使用LV-STAT3 siRNA或AZD0530可以抑制小鼠的肿瘤生长,但与单独使用LV-STAT3 siRNA或AZD0530相比,联合治疗具有更显着的效果。根据体外和体内试验的结果,LV-STAT3 siRNA与AZD0530的联合治疗可增强对胶质母细胞瘤的治疗效果,从而支持LV-STAT3 siRNA与AZD0530的组合可作为一种新型且有效的方法打击胶质母细胞瘤的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号